Arcellx (ACLX) Net Income towards Common Stockholders (2021 - 2025)

Arcellx (ACLX) recorded quarterly Net Income towards Common Stockholders of -$58.1 million in Q4 2025, down 4.18% quarter-over-quarter from -$55.8 million in Q3 2025, and down 23.43% on a YoY basis from -$75.9 million in Q4 2024.

Arcellx (ACLX) Net Income towards Common Stockholders (2021 - 2025) Analysis & Trends

Arcellx's Net Income towards Common Stockholders history runs 5 years deep, the most recent figure standing at -$58.1 million for Q4 2025.

  • In Q4 2025, Net Income towards Common Stockholders fell 23.43% year-over-year to -$58.1 million; the TTM figure through Dec 2025 stood at -$228.9 million (down 113.39% YoY), while the FY2025 annual figure was -$228.9 million, down 113.26% from the prior year.
  • Net Income towards Common Stockholders was -$58.1 million for Q4 2025 at Arcellx, down from -$55.8 million in the prior quarter.
  • In the past five years, Net Income towards Common Stockholders ranged from a high of $19.8 million in Q4 2023 to a low of -$92.9 million in Q3 2022.
  • Historically, Net Income towards Common Stockholders has averaged -$33.0 million across 5 years, with a median of -$27.3 million in 2023.
  • The sharpest annual moves came in 2023 and 2025: Net Income towards Common Stockholders soared 150.89% in 2023, then tumbled 765.1% in 2025.
  • A 5-year view of Net Income towards Common Stockholders shows it stood at -$20.7 million in 2021, then plunged by 88.39% to -$39.0 million in 2022, then jumped by 150.89% to $19.8 million in 2023, then tumbled by 337.26% to -$47.1 million in 2024, then fell by 23.43% to -$58.1 million in 2025.
  • The last three Net Income towards Common Stockholders figures came in at -$58.1 million (Q4 2025), -$55.8 million (Q3 2025), and -$52.8 million (Q2 2025), per Business Quant data.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Net Income (Qtr)
1 Alterity Therapeutics 814,307.08 Bn 814,307.05 Bn - -
2 Belite Bio 55,320.00 Bn 55,320.00 Bn - -26.94 Mn
3 Quantum Biopharma 17,149.72 Bn 17,149.72 Bn - -13.56 Mn
4 Legend Biotech 3,590.00 Bn 3,589.71 Bn 242.10 Mn 2.50 Mn
5 Akari Therapeutics 1,650.72 Bn 1,650.72 Bn - -14.46 Mn
6 Evaxion A 1,522.09 Bn 1,522.07 Bn - -3.63 Mn
7 Psyence Biomedical 229.39 Bn 229.38 Bn - -1.50 Mn
8 Vertex Pharmaceuticals 113.09 Bn 105.85 Bn 2.59 Bn 1.03 Bn
9 Abivax 90.15 Bn 90.15 Bn - -56.48 Mn
10 Arcellx 6.48 Bn 6.48 Bn - -58.11 Mn

Historic Data

Download Data
DateValue
Dec 31, 2025 -58.11 Mn
Sep 30, 2025 -55.78 Mn
Jun 30, 2025 -52.77 Mn
Mar 31, 2025 -62.27 Mn
Dec 31, 2024 -47.08 Mn
Sep 30, 2024 -25.84 Mn
Jun 30, 2024 -27.16 Mn
Mar 31, 2024 -7.20 Mn
Dec 31, 2023 19.84 Mn
Sep 30, 2023 -39.34 Mn
Jun 30, 2023 -23.85 Mn
Mar 31, 2023 -27.34 Mn
Dec 31, 2022 -38.99 Mn
Sep 30, 2022 -92.87 Mn
Jun 30, 2022 -30.77 Mn
Mar 31, 2022 -26.04 Mn
Dec 31, 2021 -20.70 Mn
Sep 30, 2021 -17.11 Mn
Jun 30, 2021 -15.93 Mn
Mar 31, 2021 -11.28 Mn